Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas

Publisher： Karger

E-ISSN： 1423-0194|89|2|223-230

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.89, Iss.2, 2008-10, pp. : 223-230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Well-Differentiated Gastric Tumors/Carcinomas

By  

Neuroendocrinology, Vol. 84, Iss. 3, 2007-02 ,pp. : 158-164

Karger

Access to resources Recommend Favorite

Differential Inhibition of Growth Hormone Secretion by Analogs Selective for Somatostatin Receptor Subtypes 2 and 5 in Human Growth-Hormone-Secreting Adenoma Cells in vitro

By  

Neuroendocrinology, Vol. 73, Iss. 5, 2001-05 ,pp. : 344-351

Karger

Access to resources Recommend Favorite

Somatostatin Receptor Subtypes 2 and 5 Inhibit Corticotropin-Releasing Hormone-Stimulated Adrenocorticotropin Secretion from AtT-20 Cells

By  

Neuroendocrinology, Vol. 75, Iss. 6, 2002-06 ,pp. : 339-346

Karger

Access to resources Recommend Favorite

Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin

By  

Neuroendocrinology, Vol. 87, Iss. 1, 2007-10 ,pp. : 40-46

Karger

Access to resources Recommend Favorite

Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study

By  

Neuroendocrinology, Vol. 96, Iss. 4, 2012-04 ,pp. : 294-300

Karger

Access to resources Recommend Favorite